Hematology

Filter

EBMT Annual Meeting Scientific Committee Co-Chair: Antonio Pérez-Martínez

5 Mins

May 2026

We are leaving a transition from standard treatment to personalised treatment in the clinic. We are moving from the multi-omics era to the…

Evolving Endpoint Strategies

SINGLE clinical trial endpoints often fall short in capturing the full scope of patient experience, particularly in complex conditions…

EHA Presidential Interview: Konstanze Döhner

My top priorities as EHA President align closely with the association’s strategic roadmap, which we have developed and begun to implement…

EHA 2025 Interview: Martin Dreyling

EHA offers an incredible wealth of opportunities; it’s actually quite difficult to choose which highlights to include. We are fortunate to…

Review of the 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

THE 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held this year in the vibrant city of…

Minimal Residual Disease: Predicting Relapse in Myeloma

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual disease…

EBMT 2025 Interview: Janaki Vinnakota & Nicoletta Cieri

In this insightful interview, Janaki Vinnakota and Nicoletta Cieri speak on their individual, highly commended abstracts, to be presented…

EBMT 2025 Interview: Christian Chabannon & Edoardo Campodonico

In this interview, Christian Chabannon and Edoardo Campodonico discuss the potential of CAR-T cell therapy holds in treating cancers…

EBMT 2025 Interview: Magdalena Corona de Lapuerta

In this interview, Magdalena Corona de Lapuerta, recipient of the Jian-Jian Luan Award for Lymphoma Transplant Research, discussed her…

Loading posts...

« Previous 1 2 3 4 5 … 8 Next »